Bain uses cookies to improve functionality and performance of this site. More information can be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

We have limited Portuguese content available. View Portuguese content.

WSJ Pro Private Equity

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Large deals in the biopharma space are driving more activity in the sector while industry veterans continue to specialize

  • março 08, 2020
  • min read

WSJ Pro Private Equity

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Health care-focused private-equity firms bet big on biopharmaceutical deals in 2019, despite the regulatory scrutiny the sector has faced in recent years.

“Private equity has long been interested and invested in the ‘picks and shovels’ that fuel the biopharma industry, such as clinical research services, pharma IT and life science tools,” said Nirad Jain, a partner with Bain & Company who co-leads the firm's global health-care private-equity and corporate mergers-and-acquisitions practice.

He added that there has been an increased interest from private equity in biopharmaceutical products, services and health-care information technology supporting research-and-development and commercialization efforts.

WSJ Pro Private Equity